The National Cancer Institute is offering a grant to researchers aiming to enhance understanding of infection-related cancers, focusing on the roles of co-infection in cancer development. Priority is given to studying co-infections involving known oncogenic agents such as H. pylori and EBV, excluding HIV. Researchers exploring novel opportunities for prevention and treatment through investigating concurrent or sequential infections by multiple pathogens are encouraged to apply. The closing date for this grant opportunity is January 07, 2023.
Opportunity ID: 322693
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-062 |
| Funding Opportunity Title: | Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 22, 2019 |
| Last Updated Date: | Nov 22, 2019 |
| Original Closing Date for Applications: | Jan 07, 2023 |
| Current Closing Date for Applications: | Jan 07, 2023 |
| Archive Date: | Feb 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education County governments Small businesses City or township governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments State governments Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to investigations of co-infections with known oncogenic agents (e.g., Helicobacter pylori [H. pylori] and Epstein Barr virus [EBV]; excluding human immunodeficiency virus [HIV]) and of co-infections that engendered novel opportunities for prevention and treatment. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-062.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 322693 Full Announcement-PAR-20-062 -> PAR-20-062-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00259075 | Feb 06, 2020 | Jan 24, 2022 | View | |
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00256818 | Feb 06, 2020 | May 24, 2020 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269740 | Oct 28, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277696 | Nov 01, 2022 | Jan 07, 2023 | View |
Package 1
Mandatory forms
322693 RR_SF424_2_0-2.0.pdf
322693 PHS398_CoverPageSupplement_5_0-5.0.pdf
322693 RR_OtherProjectInfo_1_4-1.4.pdf
322693 PerformanceSite_2_0-2.0.pdf
322693 RR_KeyPersonExpanded_2_0-2.0.pdf
322693 PHS398_ResearchPlan_4_0-4.0.pdf
322693 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
322693 RR_Budget_1_4-1.4.pdf
322693 RR_SubawardBudget30_1_4-1.4.pdf
322693 PHS398_ModularBudget_1_2-1.2.pdf
322693 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
322693 RR_SF424_2_0-2.0.pdf
322693 PHS398_CoverPageSupplement_4_0-4.0.pdf
322693 RR_OtherProjectInfo_1_4-1.4.pdf
322693 PerformanceSite_2_0-2.0.pdf
322693 RR_KeyPersonExpanded_2_0-2.0.pdf
322693 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
322693 RR_Budget_1_4-1.4.pdf
322693 RR_SubawardBudget30_1_4-1.4.pdf
322693 PHS398_ModularBudget_1_2-1.2.pdf
322693 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
322693 RR_SF424_5_0-5.0.pdf
322693 PHS398_CoverPageSupplement_5_0-5.0.pdf
322693 RR_OtherProjectInfo_1_4-1.4.pdf
322693 PerformanceSite_4_0-4.0.pdf
322693 RR_KeyPersonExpanded_4_0-4.0.pdf
322693 PHS398_ResearchPlan_4_0-4.0.pdf
322693 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
322693 RR_Budget_3_0-3.0.pdf
322693 RR_SubawardBudget30_3_0-3.0.pdf
322693 PHS398_ModularBudget_1_2-1.2.pdf
322693 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 4
Mandatory forms
322693 RR_SF424_5_0-5.0.pdf
322693 PHS398_CoverPageSupplement_5_0-5.0.pdf
322693 RR_OtherProjectInfo_1_4-1.4.pdf
322693 PerformanceSite_4_0-4.0.pdf
322693 RR_KeyPersonExpanded_4_0-4.0.pdf
322693 PHS398_ResearchPlan_5_0-5.0.pdf
322693 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
322693 RR_Budget_3_0-3.0.pdf
322693 RR_SubawardBudget30_3_0-3.0.pdf
322693 PHS398_ModularBudget_1_2-1.2.pdf
322693 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
